Tech Company Financing Transactions
Synchroneuron Funding Round
Synchroneuron closed a $6 million Series A financing round on 2/7/2012. Investors included Morningside Group.
Transaction Overview
Company Name
Announced On
2/7/2012
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Series A
Investors
Morningside Group (Isaac Cheng)
Proceeds Purpose
The company did not state what it intended to do with the funds, but it did note that it expects to start Phase 1 clinical trials this year for a new drug therapy to treat Tardive dyskinesia.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1188 Centre St.
Newton, MA 02466
USA
Newton, MA 02466
USA
Phone
Website
Email Address
Overview
Synchroneuron Inc., a Waltham, Mass.-based biopharmaceutical company that develops new therapies for tardive dyskinesia (TD) and other related movement disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
William Kerns
Chief Financial Officer
Marc Cote
Chief Scientific Officer
Barry Fogel
VP - Bus. Development
Kei-Lai Fong
Browse more venture capital transactions:
Prev: 2/7/2012: Xceleron venture capital transaction
Next: 2/8/2012: Pasteurization Technology Group venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs